Corporate social responsibility in global health: An exploratory study of multinational pharmaceutical firms

Globalization and Health

Volumn 11, Issue 1, 2015, Pages

  Droppert, Hayley ^a   Bennett, Sara ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Corporate social responsibility; Emerging markets; Global health; Pharmaceutical firms; Public private partnerships

Indexed keywords

DEVELOPING WORLD; HEALTH GEOGRAPHY; HEALTH POLICY; HEALTH SERVICES; MULTINATIONAL ENTERPRISE; ORGANIZATIONAL FRAMEWORK; PHARMACEUTICAL INDUSTRY; PUBLIC HEALTH; PUBLIC-PRIVATE PARTNERSHIP; STRATEGIC APPROACH;

ARTICLE; COMMERCIAL PHENOMENA; CORPORATE SOCIAL RESPONSIBILITY; DEVELOPING COUNTRY; DRUG COST; DRUG INDUSTRY; DRUG RESEARCH; EXPLORATORY RESEARCH; HEALTH CARE SYSTEM; HEALTH IMPACT ASSESSMENT; HUMAN; MEDICAL PRACTICE; NATIONAL HEALTH SERVICE; ORGANIZATIONAL STRUCTURE; PERSONNEL MANAGEMENT; PRESCRIPTION; PRIORITY JOURNAL; PROGRAM SUSTAINABILITY; PUBLIC-PRIVATE PARTNERSHIP; SOCIAL BEHAVIOR; SOCIAL MARKETING; STANDARDIZATION; ETHICS; HEALTH; ORGANIZATION;

DRUG INDUSTRY; GLOBAL HEALTH; HUMANS; ORGANIZATIONAL CULTURE; PUBLIC-PRIVATE SECTOR PARTNERSHIPS; SOCIAL RESPONSIBILITY;

EID: 84928007748     PISSN: None     EISSN: 17448603     Source Type: Journal    
DOI: 10.1186/s12992-015-0100-5     Document Type: Article

References (24)

1. Porter ME, Kramer MR. The competitive advantage of corporate philanthropy. Harv Bus Rev. 2002;80:56-68. 133.
2. United Nations (UN). Global Compact: Corporate Sustainability in The World Economy. 2014. https://www.unglobalcompact.org/index.html. Accessed 25 April 2014.
3. Chhabra E. Corporate Social Responsibility: Should It Be A Law? Forbes. 2014. http://www.forbes.com/sites/eshachhabra/2014/04/18/corporate-social-responsibility-should-it-be-a-law/. Accessed 17 February 2014.
4. Blowfield M, Frynas JG. Setting new agendas: critical perspectives on corporate social responsibility in the developing world. Intl Affairs. 2005;81:499-513.
5. Hopkins M. Corporate social responsibility: Is business the solution? London: Earthscan; 2007.
6. Gruskin S, Raad Z. Are drug companies living up to their human rights responsibilities? Moving toward assessment. PLoS Med. 2010;7:e1000310.
7. Lee J-Y, Hunt P. Human rights responsibilities of pharmaceutical companies in relation to access to medicines. J Law Med Ethics. 2012;40:220-33.
8. Ritter GS. Are drug companies living up to their human rights responsibilities? The merck perspective. PLoS Med. 2010;7:e1000343.
9. The PLoS Medicine Editors. Drug companies should be held more accountable for their human rights responsibilities. PLoS Med. 2010;7:e1000344.
10. Vian T, McCoy K, Richards SC, Connelly P, Feeley F. Corporate social responsibility in global health: the Pfizer Global Health Fellows International Volunteering Program. Hum Resour Plan J. 2007;30:30-5.
11. Mahmud A, Parkhurst M. The role of the health care sector in expanding economic opportunity. Corporate social responsibility initiative report No. 21. Cambridge, MA: Kennedy School of Government, Harvard University; 2007.
12. Leisinger KM. The corporate social responsibility of the pharmaceutical industry: idealism without illusion and realism without resignation. Bus Ethics Q. 2005;15:577-94.
13. UN. CSR and Developing Countries: What Scope for Government Action? Sustainable Development Innovation Briefs. Policy Integration and Analysis Branch of the Division for Sustainable Development; 2007. https://sustainabledevelopment.un.org/content/documents/no1.pdf. Accessed 19 February 2014.
14. Brundtland GH. Our Common Future: Report of the World Commission on Environment and Development. Geneva: United Nations; 1987. http://www.un-documents.net/our-common-future.pdf. Accessed 19 February 2014.
15. Franklin D. Just Good Business. The Economist 2008. http://www.economist.com/node/10491077. Accessed 27 February 2014.
16. European Commission: Corporate Social Responsibility (CSR). http://ec.europa.eu/growth/industry/corporate-social-responsibility/index_en.htm. Accessed 9 April 2015.
17. Lee M, Kohler J. Benchmarking and transparency: incentives for the pharmaceutical Industry's corporate social responsibility. J Bus Ethics. 2010;95:641-58.
18. Tolve A. Pharma and CSR: Why good deeds are good business. Eye for Pharma. 2011. http://social.eyeforpharma.com/commercial/pharma-and-csr-why-good-deeds-are-good-business. Accessed 9 April 2015.
19. Hwang JJ. Is Merck's Corporate Social Responsibility Good for the Global Health? U of California San Diego. 2012. http://irps.ucsd.edu/assets/001/503692.pdf. Accessed 20 March 2014.
20. Peterson K, Rehrig M, Stamp M, Kim S. Competing by Saving Lives: How Pharmaceutical and Medical Device Companies Create Shared Value in Global Health. FSG. 2012. http://www.fsg.org/Portals/0/Uploads/Documents/PDF/Competing_Saving_Lives.pdf. Accessed 18 December 2013.
21. Margolis JD, Walsh JP. People and profits? The search for a link between a Company's social and financial performance. Mahwah, NJ: Lawrence Erlbaum Associates; 2001.
22. Momin MA, Parker LD. Motivations for corporate social responsibility reporting by MNC subsidiaries in an emerging country: The case of Bangladesh. Br Account Rev. 2013;45:215-28.
23. Attard J. Access to medicine index: Can a global scorecard framework increase access to essential medicines in developing countries? Sanford J Public Policy. 2014;5:1-23.
24. Peters DH, Paina L, Bennett S. Expecting the unexpected: applying the Develop-Distort Dilemma to maximize positive market impacts in health. Health Policy Plan. 2012;27 suppl 4:iv44-53.